QILU ANTIBIOTICS
GenericsQILU ANTIBIOTICS is a generic drug manufacturer focused on Infectious Disease, Dermatology.
QILU ANTIBIOTICS at a Glance
- Growing R&D activity with 84 trials in last 2 years
- Fast trial execution (10 months median completion)
QILU ANTIBIOTICS's Key Drugs
QILU ANTIBIOTICS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
QILU ANTIBIOTICS's Recent FDA Approvals
New NDA/BLA approvals for QILU ANTIBIOTICS over the last two years — novel drugs only, excluding generics and label supplements.
QILU ANTIBIOTICS's Therapeutic Areas
QILU ANTIBIOTICS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
QILU ANTIBIOTICS's Top Competitors
QILU ANTIBIOTICS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
QILU ANTIBIOTICS Pipeline Snapshot
Active clinical trials for QILU ANTIBIOTICS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 8/46 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2015-12-28
- Latest
- 2024-10-31
- Applications
- 6
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges